Login
Companies $ALNY
$160.14 +$0.41 (0.26%) After hours
ALNYLAM PHARMACEUTICALS, INC. logo

ALNYLAM PHARMACEUTICALS, INC.

alnylam.com

What Do They Do?

Develops and sells RNAi medicines for people with rare and common diseases, and works with pharmaceutical companies to develop and commercialize additional treatments.

How Do They Make Money?

Alnylam sells its medicines to healthcare providers, with product sales counted when customers receive the products. It also earns collaboration revenue through agreements that let partners use its technology and develop candidates, and royalties on sales of products commercialized by collaborators.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Net product revenues
Sold outright

80%
FY2022: 86%
Net revenues from collaborations
15%
FY2022: 13%
Royalty revenue
Licensed
4.7%
FY2022: 0.8%

Who Are Their Customers?

Alnylam sells medicines to qualified healthcare providers, including customers that purchase directly. Novartis commercializes Leqvio and Sanofi commercializes Qfitlia.

Do Revenues Turn Into Profits?

Yes. It kept 8 cents of every revenue dollar as net income in FY2025 and turned 13 cents into free cash flow.

Operating income, FY2025
14% of revenue
▲ Turned profitable vs FY2024 (−$176.9M, −8%)
Net income, FY2025
8% of revenue
▲ Turned profitable vs FY2024 (−$278.2M, −12%)
Free cash flow, FY2025
13% of revenue
▲ Turned profitable vs FY2024 (−$42.6M, −2%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +17%
vs $1.2B in Q3 FY2025
Net income
▲ +641%
vs $292.7M in Q3 FY2025
Net product revenues share of revenue vs 68.1% in Q3 FY2025
  • Jul 30, 2026 Alnylam lowered its 2026 TTR product sales guidance It cut the full-year TTR net product revenue range from $4,400 to $4,700 million to $4,200 to $4,500 million.

Growing. Revenue grew 4.4x in 4 years, from $844.3M in FY2021 to $3.7B in FY2025, about 45% a year.

Broader AMVUTTRA use The older report described AMVUTTRA as approved for polyneuropathy, with cardiomyopathy still in development; the latest report describes approval for cardiomyopathy too.

Fitusiran enters commercialization The older report describes fitusiran as a hemophilia program being advanced by Sanofi; the latest report says Sanofi is commercializing Qfitlia, which has approvals for hemophilia.

Revenue over time
Net product revenues Net revenues from collaborations Royalty revenue
$5B$2.5B$0

Who Do They Compete With?

Competes with ADARx Pharmaceuticals, Amgen, Argo Biopharmaceutical, Aro Biotherapeutics, Arrowhead Pharmaceuticals, AstraZeneca, Dyne Therapeutics, Eli Lilly, GlaxoSmithKline, Novo Nordisk, SanegeneBio, Sarepta Therapeutics, Silence Therapeutics, Takeda Pharmaceutical, Wave Life Sciences, Ionis, Intellia, Pfizer, BridgeBio Pharma, and Bayer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support